Next Day Disclosure Return
Filed with HKEX · Stock code 2595 · · 6 pages · English
Genfleet Therapeutics (Shanghai), Inc. on 6ix
Earlier from Genfleet Therapeutics (Shanghai)
- VOLUNTARY ANNOUNCEMENT First Patients Dosed Respectively in China and Overseas in a Combinational Study of GFH276 (Pan RAS Inhibitor), with Three Front-line Combination Regimens Treating Pancreatic Cancer to be Evaluated in Phase II Trial
- VOLUNTARY ANNOUNCEMENT Announcement on the Progress of Share Repurchase
- Share repurchase
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026
Follow Genfleet Therapeutics (Shanghai) into a list and get an email when it puts out news.
Follow Genfleet Therapeutics (Shanghai)